Contact Information: Contact: Michael F. Brigham President and Chief Executive Officer (207) 878-2770 Ext. 3106
ImmuCell Announces Cross-License With Anadis
| Source: ImmuCell Corporation
PORTLAND, ME--(Marketwire - March 12, 2008) - ImmuCell Corporation (NASDAQ : ICCC ) today
announced that it had entered into a cross-license of technology with
Anadis Limited (ASX : ANX ) of Australia.
ImmuCell granted Anadis an exclusive, worldwide license to the human and
environmental applications of its milk antibody technology. Under this
agreement, ImmuCell is not obligated to fund further product development
and is entitled to receive a royalty on any sales achieved by Anadis
utilizing the technology.
In return, ImmuCell was granted a license to the production technology and
capabilities of Anadis in Australia. ImmuCell is obligated to pay Anadis a
royalty on any sales of First Defense® manufactured in collaboration with
Anadis in Australia.
Anadis is an Australian-based biotechnology company focused on milk derived
polyclonal antibodies and other milk-derived bioactives for human and
environmental health applications.
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries. Press releases and other
information about the Company are available at http://www.immucell.com.